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Mixed Histocytosis
Manifesting as Suprasellar Mass with Aortic Involvement
Hayk Papukhyan MD; Connor Kerndt, OMS-III; Gurinder Gakhal MD; Prashant Patel MD
Department of Internal Medicine

Learning Objectives
 Define Histiocytoses, L-CH, N-LCH, and Mixed Histiocytosis
 Explain the spectrum of L-type histiocytosis
 Discuss difference in organ system involvement
 Examine difficulty in diagnosis
 Discuss importance of imaging, cytology, and clinical suspicion in diagnosis
 Review classification schema and treatment

Introduction
 Histiocytoses are group of disorders affecting myeloid progenitor cells
 The etiopathogenesis of histiocytoses are largely unknown, but BRAF-V600E mutation is frequently
implicated in the pathogenesis of these conditions
 Histiocytoses are grouped into L-C-M-R-H classification presenting with various symptomology,
cytology, and prognosis dependent on category
 The L-group includes Langerhan, Non-Langerhan, and Mixed histiocytosis
 Langerhan Cell Histiocytosis (LCH) incidence is one case per million adults
 Non-Langerhan Cell Histiocytosis (N-LCH) have only 500 documented cases and Mixed
Histiocytosis only around 100 cases (2+ others)
 Histiocytoses clinical manifestations vary depending on organ involvement
 LCH has been known to affect long bones, skin, lymph nodes, spleen, and CNS
 N-LCH can affect long bones, maxillary sinuses, large blood vessels, heart, CNS, skin and pituitary
gland (2)
 Diagnosis is made with tissue biopsy with cytology, clinical manifestations, and imaging showing
multisystem involvement
 Cytology testing include CD1a, CD68, CD163, CD207, S100, BRAFV600E,
 LCH and N-LCH carry a poor prognosis, which worsens with CV and CNS involvement
 Treatment for LCH, N-LCH, and Mixed Histiocytosis vary so differentiation is important
 LCH treatment is centered off radiation, resection, and targeted chemotherapy
 N-LCH has no standardized treatment but trials show benefit with adding PEG-a unlike LCH

Case Presentation
In August, A 42-year-old white female with a past medical history of migraines, depression, and
fibromyalgia initially presented to Henry Ford Macomb Hospital after a syncopal event. The event
occurred after having sutures removed one week status-post tenosynovitis release surgery and was
transported to the ER immediately for evaluation.
Upon arrival, the patient was feeling light-headed with associated headaches, visual changes,
diaphoresis and fatigue which she had not experienced in the past. The patient denied symptoms of
fever, shortness of breath, nausea, vomiting, focal weakness, or loss of sensation. The patient family
history and social history were both unremarkable. Her past surgical history was significant for
tenosynovitis release, cholecystectomy, sleeve gastroplasty, and umbilical hernial repair. The patient
has no known drug allergies. The patient medications included cetirizine, cyclobenzaprine, duloxetine,
lortab, ibuprofen, ativan, omeprazole, sertraline, tizanidine, and tramadol. Physical exam was notable
for an anxious woman in mild distress, appearing pale, no obvious signs of trauma, normal heart and
lung sounds, no abdominal tenderness, and no focal neurologic deficits. The patients vitals revealed a
blood pressure of 71/47mmHg, HR 84bpm, 97.2 °F temporally, RR 16rpm, and SpO2 96% on room air.
Initially the event was presumed to be vasovagal in nature but a syncopal workup ensued with an EKG,
CTA CT head and neck, and blood work. EKG was abnormal with a prolonged QT interval of 612
which was not previously diagnosed. CTA with pulmonary embolism protocol incidentally found
inflammation of the aorta and left subclavian vessel with mural thickening of descending aortic arc,
CTA also showed stenosis of the celiac, superior mesenteric, and renal arteries. This finding was
suspicious of Takayasu arteritis. CT head and neck revealed 14mm hypothalamic mass with optic
chiasm involvement—however the patient denied visual impairment. The patient was discharged with
plans to follow up with her rheumatologist and neurosurgery for evaluation of her hypothalamic mass.
In December 2018, due to worsening of vision, A MRI imaging of the patients brain was obtained
showing enlargement of the hypothalamic mass, measuring 21.3mm with associated intermittent
horizontal diplopia occurring daily with continued fever, fatigue, and cold intolerance. Within a month,
the patient had a right craniotomy preformed with partial tumor resection and was complicated by postoperative cerebral edema and uncal herniation. Patient was given Decadron and intubated for a week to
preserve the airway. The patient subsequently developed diabetes insipidus which was treated with
desmopressin. Endocrinology diagnosed panhypopituitarism secondary to resection and hormone
replacement therapy was initiated. The patient is still being treated for her condition.
Final pathology reports revealed BRAF positive Langerhans Cell Histiocytosis, staining positive for
CD1a, S-100, Langerin, CD68 and CD168. Two weeks later, the patient was discharged home after
stabilization.

Clinical Imaging

As elucidated by this case, histiocytoses can be a difficult diagnosis and require adept clinical
suspicion. Presentations vary greatly as a result of different organ involvement, from syncope from
SIADH, to bone pain from lytic lesions. It is important to consider N-LCH, LCH, and Mixed
histiocytosis in patients with osteolytic lesions and vascular or skin involvement. Histiocytoses can
frequently inflict different organ systems thus clinical consideration should be given in patients with
odd presentations that cannot be attributed to a particular cause especially when bone, skin, and
vasculature are involved. In this case, the patients vascular involvement mimicked a vasculitis—
Takayasu arteritis—with aortitis, subclavian, and renal artery infliction but further evaluation
illustrated a histiocytosis picture.
The different and hard to recognize presentations, such as this case makes classification of
histiocytoses difficult as well. The subclassifications within the L-group of LCH, N-LCH, and Mixed
histiocytosis are nebulous. Cases of these conditions are exceptionally rare which make the
classification system difficult to effectively distinguish. The classification of these groups are
primarily cytologic, but is this the best way to classify these conditions clinically? These processes
pathogenesis are widely unknown, but are known be error in myeloid progenitors differentiation—
presumptively at different locations. This could provide context to why the tumors cell markers vary
even amongst the same class. The biopsy for this case revealed CD-1a positive yet its CD-163/CD-68
positivity technically classifies it “Non-Langerhan Cell”. Different lesions, such as this patients,
doesn’t fit distinctly into any of the three as aforementioned categories which makes the current
schema seem relatively ineffective. This patients clinical presentation with vascular involvement was
more consistent with N-LCH; however, the cytology was inconclusive between LCH and N-LCH—
making it more consistent with mixed histiocytosis. Since cytology can be inconclusive especially in
light of clinical findings, it makes the L-group of histiocytosis seem to be more of a spectrum of
disease rather than distinct categories.
LCH and N-LCH are important to differentiate as their management strategies differ in approach
although there treatment guidelines are not well established. It is important to to recognize that these
two disease processes can occur together manifesting as “mixed histiocytosis”. In patients with mixed
histiocytosis with a BRAF V600E mutation Vemurafenib is recommended non-dependent on origin. If
the patient can not tolerate Vemurafenib then the patient is treated with pegylated interferon alfa or
MEK inhibitor. In patients without the BRAF mutation, conventional or pegylated interferon alfa is
used and followed by then Cladribine and Cyclophosphamide in patients that cannot tolerate or fail
interferon-a. Patients are often encouraged to enroll in clinical trials as there is not many set guidelines
of treatment due to the rare nature of disease.
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Mass effect upon the hypothalamus and optic chiasm
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Conclusion
 Histiocytoses present as a rare spectrum of disease with different presenting symptoms

Figure 2 (above right): MR-Angiography of Chest/Abdomen
Multiple findings consistent with Takayasu Arteritis
Diffuse mural thickening of the aortic arch + descending thoracic aorta—thickness (6mm)
Moderate stenoses of the proximal portions of the left subclavian artery and common carotids

 Differences in diagnosis depends primarily on cytology and organ system involvement
 Treatment protocols vary for different histiocytosis although guidelines are not well established
 Patients that present under these rare condition should consider enrolling in clinical trials

